Recruiting

NCT Number: NCT07358910

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.

RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.

Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Dengue Adenophorea Infections Adenoviridae Infections Adenovirus Alphavirus Infections Animal Diseases Arbovirus Infections Arenaviridae Infections Arenavirus Infections Ascaris Lumbricoides Bacterial Infections Bacterial Infections and Mycoses Bordetella Infections Brain Diseases Brucellosis Bunyaviridae Infections Burkholderia Infections Caliciviridae Infections Central Nervous System Diseases Central Nervous System Infections Central Nervous System Viral Diseases Chickenpox Chikungunya Chikungunya Fever Chlamydia Chlamydia Infections Chlamydiaceae Infections Clonorchis Sinensis Clostridium Infections Communicable Diseases Cytomegalovirus DNA Virus Infections Digestive System Diseases Diphteria Disease Attributes Elephantiasis, Filarial Encephalitis Encephalitis, Arbovirus Encephalitis, Japanese Encephalitis, Tick-Borne Encephalitis, Viral Enoplida Infections Entamoeba Histolytica Enterovirus Enterovirus Infections Epstein Barr Virus Epstein-Barr Virus Infections Euglenozoa Infections Filariasis Flaviviridae Infections Flavivirus Infections Gastrointestinal Diseases Genital Diseases Giardiasis Gram-Negative Bacterial Infections Gram-Positive Bacterial Infections Hantavirus Infections Helminthiasis Hemic and Lymphatic Diseases Hemorrhagic Fevers, Viral Henipavirus Infections Hepatitis Hepatitis A Hepatitis E Hepatitis, Animal Hepatitis, Viral, Animal Hepatitis, Viral, Human Herpesviridae Infections Human Papilloma Virus (HPV) Infections Infectious Encephalitis Influenza A and B Intestinal Diseases Intestinal Diseases, Parasitic Japanese Encephalitis Legionella Pneumophila Pneumonia Leishmaniasis Leptospirosis Liver Diseases Lymphatic Diseases Lymphatic Filariasis Lymphedema Malaria Mayaro Fever Measles Melioidosis Meningitis Mononegavirales Infections Morbillivirus Infections Mosquito-Borne Diseases Mouth Diseases Mumps Mycoplasma Mycoplasma Infections Mycoplasmatales Infections Neglected Diseases Nematode Infections Nervous System Diseases Neuroinflammatory Diseases Nipah Virus Infection Norovirus Infections Opisthorchis Viverrini Oropouche Fever Paramyxoviridae Infections Parasitic Diseases Parotid Diseases Parotitis Parvoviridae Infections Parvovirus Pathologic Processes Pathological Conditions, Signs and Symptoms Pertussis Picornaviridae Infections Protozoan Infections Q Fever RNA Virus Infections Reoviridae Infections Respiratory Syncytial Virus (RSV) Respiratory Tract Diseases Respiratory Tract Infections Rhinovirus Rift Valley Fever Rotavirus Disease Rotavirus Infections Rubella Rubivirus Infections Rubulavirus Infections Salivary Gland Diseases Salmonella Typhi Schistosomiasis Secernentea Infections Severe Fever With Thrombocytopenia Syndrome Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial Skin Diseases Skin Diseases, Infectious Skin Diseases, Parasitic Skin and Connective Tissue Diseases Spirochaetales Infections Spirurida Infections Stomatognathic Diseases Streptococcus Pneumoniae Strongyloides Stercoralis Infection Tetanus Tick-Borne Diseases Tick-borne Encephalitis (TBE) Togaviridae Infections Toxoplasma Gondii Trematode Infections Trichuriasis Trichuris Trichiura Tumor Virus Infections Urogenital Diseases Usutu Virus Infection Vaccine-Preventable Diseases Varicella Varicella Zoster Virus Infection Vector Borne Diseases Vibrio Cholerae Virus Diseases West Nile Virus Whooping Cough Yellow Fever Zika Virus Infection Zoonoses

Age range

2 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Pasteur du Cambodge

Phnom Penh, 12201, Cambodia

Location status: Recruiting

Location contact

Claude Flamand, Ph.D

PRINCIPAL_INVESTIGATOR

Erik Karlsson, Ph.D

SUB_INVESTIGATOR

Sokleaph CHENG, Ph.D

SUB_INVESTIGATOR

Sopheak SORN, MSc.

CONTACT

[email protected]

+855 12 268 660

Sowath LY, MD, Ph.D

CONTACT

[email protected]

+855 69 322 031

Sébastien Boyer, Ph.D

SUB_INVESTIGATOR

Tephanie Sieng, Ph.D

SUB_INVESTIGATOR

About this study

RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Residency in the village for more than 6 months;
Age between 2 and 75 years old at the time of inclusion;
For adults: provision of written consent;
For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;

Exclusion criteria

Unable to understand or consent;
Under guardianship or deprived of liberty;
Medical conditions that impede survey participation;
Refusal to participate in the study.

Treatment and study plan

Primary outcomes

Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:

Time frame: At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.

The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.

Study contacts

Contact information is provided by the study sponsor or research team.

Claude Flamand, Ph.D.

CONTACT

[email protected]

+855012333650

Najet Hadhri, MSc.

CONTACT

[email protected]

+34661400698

Sponsors and collaborators

Lead sponsor

Institut Pasteur du Cambodge

Other

Collaborators

CDC - Ministry of Health of Cambodia
Institut Pasteur
Malaria Consortium
Ministry of Agriculture, Forestry and Fisheries Cambodia
UMR ASTRE (CIRAD)

Registry information

Acronym: RACSMEI

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Jan 22, 2026
Registry last updated: Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed